Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study
Titel:
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study
Auteur:
Sangro, Bruno Kudo, Masatoshi Erinjeri, Joseph P Qin, Shukui Ren, Zhenggang Chan, Stephen L Arai, Yasuaki Heo, Jeong Mai, Anh Escobar, Jose Lopez Chuken, Yamil Alonso Yoon, Jung-Hwan Tak, Won Young Breder, Valeriy V Suttichaimongkol, Tanita Bouattour, Mohamed Lin, Shi-Ming Peron, Jean-Marie Nguyen, Quang T Yan, Lunan Chiu, Chang-Fang Santos, Florinda A Veluvolu, Anil Thungappa, Satheesh Chiradoni Matos, Marco Żotkiewicz, Magdalena Udoye, Stephanie I Kurland, John F Cohen, Gordon J Lencioni, Riccardo